メタスタティック・ラテンシーとWNTのオトクリン阻害による免疫回避
Srinivas Malladi1, Danilo G Macalinao2, Xin Jin1
1Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cell
|March 26, 2016
まとめ
潜伏転移は,原発腫瘍の除去後何年も生存する癌細胞を意味します. これらの細胞は 潜伏能力のある癌細胞 (LCC) と呼ばれ 免疫監視から逃れ 休眠状態に入ります
科学分野:
- 腫瘍学
- 癌 生物学
- 免疫学
背景:
- メタスタシスは,原発腫瘍の除去から数年後にも起こり得る.
- 癌細胞の長期休眠状態とその後の増殖を可能にするメカニズムは十分に理解されていません.
- 拡散した腫瘍細胞は 潜伏状態で生き残るために 免疫の検出を回避しなければなりません
研究 の 目的:
- 癌細胞が転移時に潜伏状態で生き残るメカニズムを特定し,特徴づけること.
- 休眠中の転移細胞の腫瘍発症の可能性を維持する要因を定義する.
- 潜伏した癌細胞が 免疫監視を回避する方法を 理解するためです
主な方法:
- 人間の肺癌と乳癌の細胞系から潜伏能力のある癌細胞 (LCC) の分離.
- 転写因子とシグナル伝達経路に焦点を当てた遺伝子発現の分析
- NK細胞の相互作用を含む細胞サイクル状態と免疫回避機構の評価
主要な成果:
- LCC細胞は幹細胞のような性質を持ち,SOX2とSOX9の転写因子を発現する.
- LCC細胞によるDKK1発現は遅い循環状態を誘導し,NK細胞のクリアランスを回避してULBPリガンドをダウンレギュレーションします.
- SOX依存性幹状状態とWNTシグナル伝達阻害により,LCC細胞は静止状態に入り,先天的な免疫を回避することができます.
結論:
- 潜伏能力のある癌細胞は,長期間休眠状態を生き延びるために,幹細胞のような特性と免疫回避戦略を利用します.
- SOX2/SOX9発現とWNT経路の阻害は,潜在的転移状態を維持するために重要である.
- これらのメカニズムの理解は,遅い転移性再発を予防または治療するための潜在的な治療目標を提供します.
関連する概念動画
Canonical Wnt Signaling Pathway
10.9K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.9K
Non-Canonical Wnt Signaling Pathways
8.6K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.6K
Non-Canonical Wnt Signaling Pathways
1.9K
1.9K
Metastasis
6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K
The Tumor Microenvironment
8.1K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K


